ReviewMaedica2025
Pregnancy Outcomes in Women with Multiple Sclerosis Who Had Exposure to Rituximab: a Systematic Review and Meta-Analysis.
Review in Maedica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Disease Course, Outcomes, and Complications in Pregnant and Breastfeeding Women with Multiple Sclerosis Treated with Rituximab or Ocrelizumab: A Narrative Review.Journal of research in pharmacy practice · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe designed this study to estimate pooled prevalence of preterm and term deliveries of women exposed to rituximab before pregnancy.
methodsA systematic review using PRISMA guideline was conducted. We performed a comprehensive search in PubMed, Scopus, EMBASE and Web of Science databases based on a predefined search strategy. The search was done on the 1st of May 2023 and there were no time or language limitations. Data were analyzed using random effect model and all estimated effect sizes were reported at a confidence interval of 95%. Also, we used the I-square index (I²) to assess statistical heterogeneity.
resultsA literature search revealed 4059 records, of which 26 full-texts were evaluated, and finally, five studies remained for the systematic review. The pooled prevalence of term pregnancy in women with multiple sclerosis who were treated with rituximab was 64% (95% CI 31-96%) (I²=95.1%, P <0.001). The pooled prevalence of preterm pregnancy in women with MS who were treated with rituximab was 4% (95% CI 1-9%) (I²=16.6%, P=0.3).
conclusionThe findings of this systematic review and meta-analysis indicate that rituximab exposure during conception is not associated with an increased rate of preterm deliveries.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.